Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 9/20 | 0.52 |
| ▸ | ESR1 | P03372 | 4/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999204 | 1.00 | PRKCI (0.52) | PRKCIESR1PDE10APDE4APDE4B | |
| SCHEMBL7678980 | 0.88 | PDE5A (0.51) | PRKCIESR1PDE10APDE4APDE4B | |
| SCHEMBL29998653 | 0.88 | PRKCI (0.51) | PRKCIESR1PDE10APDE4APDE4B | |
| SCHEMBL23498498 | 0.88 | PRKCI (0.51) | PRKCIESR1PDE10APDE4APDE4B | |
| SCHEMBL23518886 | 0.81 | SMN1; SMN2 (0.51) | PRKCIESR1PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL31220566 | 0.80 | SMN1; SMN2 (0.50) | PRKCIESR1PDE4APDE4BPDE4C | |
| SCHEMBL31220378 | 0.80 | PRKCI (0.42) | PRKCIESR1 | |
| SCHEMBL7677294 | 0.79 | PRKCI (0.44) | PRKCIESR1PDE4B | |
| SCHEMBL25417184 | 0.79 | PRKCI (0.45) | PRKCIPDE10APDE4APDE4BPDE4C | |
| SCHEMBL30404769 | 0.79 | PRKCI (0.45) | PRKCIPDE10APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-14 | — | — | US | claimed |
| EP-4398988-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | claimed |
| EP-4288059-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023039370-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | claimed |
| EP-4072677-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| WO-2022169868-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC. (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021118929-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | claimed |
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057568-A1 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SNRPB2, SYNCRIP, HNRNPUL2 | PRKCI 1224/4885ESR1 4827/4885PDE10A 373/4885 |
| US-20240043444-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | PRKCI 2314/4885ESR1 4875/4885PDE10A 189/4885 |
| US-20240374602-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | PRKCI 3662/4885ESR1 4876/4885PDE10A 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.